Sanofi (SNY) vs Vertex Pharmaceuticals (VRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vertex Pharmaceuticals (VRTX) has outperformed Sanofi (SNY) over the past year, gaining 20.7% versus a loss of 6.3%. Over five years, VRTX leads with a +180.5% price change compared with -3.7% for SNY. Vertex Pharmaceuticals is the larger company by market cap ($130.58 billion vs $111.70 billion), about 1.2 times the size.
On valuation, Sanofi trades at a lower forward P/E (8.6x vs 25.9x for Vertex Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNY | VRTX |
|---|---|---|
| Share price | $46.52 | $515.02 |
| Market cap | $111.70B | $130.58B |
| 1-day change | +1.00% | -1.08% |
| YTD return | -4.00% | +13.60% |
| 1-year return | -6.27% | +20.68% |
| 5-year return | -3.69% | +180.53% |
| P/E ratio (TTM) | 23.14 | 33.14 |
| Forward P/E | 8.57 | 25.86 |
| EPS (TTM) | $2.01 | $15.54 |
| Dividend yield | 5.20% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $12.00B |
| Revenue growth (YoY) | — | +8.90% |
| Net income (latest FY) | — | $3.95B |
| Gross margin | — | 86.24% |
| Operating margin | — | 34.77% |
| Net margin | — | 32.94% |
| 52-week high | $50.61 | $568.67 |
| 52-week low | $39.07 | $412.27 |
| Distance from 52-week high | -8.08% | -9.43% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +18.06% | +15.60% |
| Average volume | 3.41M | 1.25M |
| Shares outstanding | 2.40B | 253.54M |
| Employees | 74,846 | 6,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRTX has outperformed SNY by 26.9 percentage points over the past year.
- Vertex Pharmaceuticals trades at a higher earnings multiple (33.1x vs 23.1x trailing P/E).
- Sanofi offers a meaningfully higher dividend yield (5.20% vs 0.00%).
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
About Vertex Pharmaceuticals
VRTX stock →Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees
SNY vs VRTX FAQ
Which is bigger, Sanofi or Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) is larger, with a market capitalization of $130.58B compared with $111.70B for Sanofi (SNY).
Which stock has performed better over the past year, SNY or VRTX?
VRTX returned +20.68% over the past 12 months, compared with -6.27% for SNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, SNY or VRTX?
SNY has the lower trailing P/E at 23.1, versus 33.1 for VRTX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Sanofi or Vertex Pharmaceuticals?
Sanofi pays a dividend yielding 5.20%, while Vertex Pharmaceuticals does not currently pay a regular dividend.
Are Sanofi and Vertex Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.